IL-17, IL-23 and IL-12/23 biologics on SilverScript Choice (S5601-004)
Stelara and its biosimilars, Skyrizi, Tremfya, Cosentyx and Taltz, for psoriasis, psoriatic arthritis and Crohn's, checked against this plan's 2026 formulary (its list of covered drugs).
- Plan type
- Stand-alone drug plan (PDP), Connecticut + 3 more
- Premium
- $32.70/month
- Deductible
- $615.00
5 of 9 IL-17 and IL-23 biologics are covered on this plan. All 5 require prior authorization.
4 aren't on the formulary, including Wezlana and Selarsdi.
- from $1,212.25Tier 5
- from $1,212.25Tier 5
- from $2,443.44Tier 5
- from $3,762.51Tier 5
- from $8,217.12Tier 5
Not on the formulary
Wezlana, Selarsdi, Cosentyx, Taltz
Patient cost for a 30-day supply at a preferred retail pharmacy, after the $615.00 deductible where it applies. Where the plan charges a percentage (coinsurance), the dollar figure is that share of the plan's negotiated price; "from" means other strengths cost more. Data from the CMS 2026 Part D formulary and pricing files.